CI Global Health Sciences Corporate Class

Series P USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date May 2017
CAD Total net assets ($CAD)
As at 2025-08-29
$143.2 million
NAVPS
As at 2025-09-16
$8.4609
MER (%)
As at 2025-03-31
0.24
Management fee (%) 0.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.1669

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

P 90324
A ISC 301
DSC SO* 401
LL SO 1401
F 324
*No new purchases directly into switch only funds.

Performance2 As at 2025-08-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
-2.65% 4.81% 4.33% -8.87% -19.72% 2.24% 1.64% - 3.81%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.1669
2021-03-26 0.0563
2020-12-18 0.0892
2020-09-25 0.0844
2020-06-26 0.0615
Payable date Total
2020-03-20 0.1428
2019-12-13 0.0890
2019-09-27 0.0991
2019-06-21 0.0930
2019-03-22 0.1458

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series P USD
 
Portfolio allocations4 As at 2025-08-31
Asset allocation (%)
  • US Equity 84.79
  • International Equity 15.13
  • Cash and Equivalents 0.08
Sector allocation (%)
  • Healthcare 99.92
  • Cash and Cash Equivalent 0.08
Geographic allocation(%)
  • United States 84.77
  • United Kingdom 8.91
  • Switzerland 4.22
  • Denmark 2.04
  • Canada 0.06
Top holdings5
Sector (%)
1. Eli Lilly and Co Drugs 10.48%
2. AstraZeneca PLC Drugs 8.91%
3. UnitedHealth Group Inc Healthcare Services 8.53%
4. AbbVie Inc Drugs 7.99%
5. Merck & Co Inc Drugs 7.81%
6. Thermo Fisher Scientific Inc Healthcare Equipment 7.56%
7. Humana Inc Healthcare Services 6.83%
8. Intuitive Surgical Inc Healthcare Equipment 6.72%
9. Vertex Pharmaceuticals Inc Drugs 5.83%
10. IQVIA Holdings Inc Drugs 4.55%
11. Danaher Corp Healthcare Equipment 3.97%
12. Lonza Group AG Drugs 3.18%
13. Johnson & Johnson Drugs 2.97%
14. DexCom Inc Healthcare Equipment 2.80%
15. Anthem Inc Healthcare Services 2.05%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.